Identification of bioactive compounds and molecular targets of Fuke Huahuang formulation to treat vaginitis

Abstract

Background: Fuke Huahuang formulation (FHF) is widely used in the treatment of vaginitis, with clinical evidence indicating its promising anti-inflammatory properties.

Methods: We explored the bioactive components and potential mechanisms of FHF for treating vaginitis, and reveal its pharmacological activities against vaginitis.

Results: A total of 12 anti-inflammatory components in FHF and 584 pharmacological targets were identified. Furthermore, 1427 vaginitis-associated targets were identified, and 184 intersection targets between FHF and vaginitis were constructed for network analysis. Gene Ontology and pathway analysis revealed that the therapeutical targets of FHF against vaginitis are involved in modulating inflammatory stress, enhancing immunoregulation, reconstructing the microenvironment, and suppressing cell damage. Molecular docking analysis further suggested the possible direct binding of the bioactive compounds of FHF (fumarine) to the core targets, including AKT Serine/Threonine Kinase 1 (AKT1), Signal Transducer and Activator of Transcription 3 (STAT3), and nuclear factor-kappaB (NF-κB). Experimental validation found that FHF-treated vaginitis rats exhibited reduced intracellular AKT1, STAT3, and NF-κB protein expressions.

Conclusion: Overall, we identified the bioactive compounds and pharmacological mechanisms of FHF against vaginitis, thus offering a theoretical fundament for exploring FHF for treating vaginitis in the future.

Keywords

biological validation / biotargets / Fuke Huahuang formulation / mechanism / vaginitis

References

[1] Marnach ML, Wygant JN, Casey PM. Evaluation and management of vaginitis. Mayo Clin Proc. 2022; 97(2): 347-358.

[2] Sobel JD, Vempati YS. Bacterial vaginosis and vulvovaginal candidiasis pathophysiologic interrelationship. Microorganisms. 2024; 12(1): 108.

[3] Mastromarino P, Hemalatha R, Barbonetti A, et al. Biological control of vaginosis to improve reproductive health. Indian J Med Res. 2014; 140(1): 91-97.

[4] Picheta N, Piekarz J, Burdan O, Satora M, Tarkowski R, Kułak K. Phytotherapy of vulvovaginal candidiasis: a narrative review. Int J Mol Sci. 2024; 25(7): 3796.

[5] Pan Z, Wu Y, Li Y, Hu X, Zhao Y, Liu Y. Retrospective study of pathogens involved in vaginitis among Chinese women. BMC Womens Health. 2023; 23(1): 364.

[6] Tomás M, Palmeira-de-Oliveira A, Simões S, Martinez-de-Oliveira J, Palmeira-de-Oliveira R. Bacterial vaginosis: standard treatments and alternative strategies. Int J Pharm. 2020; 587: 119659.

[7] Zhou J, Qu F. Treating gynaecological disorders with traditional Chinese medicine: a review. Afr J Tradit Complement Altern Med. 2009; 6(4): 494-517.

[8] Zhao H, Zhao L, Wu F, Shen L. Clinical research on traditional Chinese medicine treatment for bacterial vaginosis. Phytother Res. 2021; 35(9): 4943-4956.

[9] Yuan Z, Pan Y, Leng T, et al. Progress and prospects of research ideas and Methods in the network pharmacology of traditional Chinese medicine. J Pharm Pharm Sci. 2022; 25: 218-226.

[10] Yang L, Xiong H, Li X, et al. Network pharmacology and comparative transcriptome reveals biotargets and mechanisms of Curcumol treating lung adenocarcinoma patients with COVID-19. Front Nutr. 2022; 9: 870370.

[11] Liu J, Meng Y, Li B, et al. Ferroptosis-related biotargets and network mechanisms of fucoidan against colorectal cancer: an integrated bioinformatic and experimental approach. Int J Biol Macromol. 2022; 222: 1522-1530.

[12] Zhao M, Wang S, Zuo A, et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett. 2021; 26(1): 40.

[13] Maczurek A, Shanmugam K, Münch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci. 2008; 1126: 147-151.

[14] Cheng L, Kaźmierczak D, Norenhag J, et al. A MicroRNA gene panel predicts the vaginal microbiota composition. msystems. 2021; 6(3): e00175-21.

[15] Vazquez F, Fernández-Blázquez A, García B. Vaginosis. Vaginal microbiota. Enferm Infecc Microbiol Clin (Engl Ed). 2019; 37(9): 592-601.

[16] Devi KP, Malar DS, Nabavi SF, et al. Kaempferol and inflammation: from chemistry to medicine. Pharmacol Res. 2015; 99: 1-10.

[17] Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients. 2016; 8(3): 167.

[18] Somanath PR, Razorenova OV, Chen J, Byzova TV. Akt1 in endothelial cell and angiogenesis. Cell Cycle. 2006; 5(5): 512-518.

[19] Di Lorenzo A, Fernández-Hernando C, Cirino G, Sessa WC. Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc Natl Acad Sci USA. 2009; 106(34): 14552-14557.

[20] Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016; 31: 1-15.

[21] Hu YS, Han X, Liu XH. STAT3: a potential drug target for tumor and inflammation. Curr Top Med Chem. 2019; 19(15): 1305-1317.

[22] Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol. 2021; 12: 716469.

[23] Joo HM, Kim KA, Myoung KS, et al. Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation. Int Immunopharmacol. 2012; 14(1): 39-46.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.